An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

• ClinicalTrials.gov Identifier: NCT02279095
• Recruitment Status: Completed
• First Posted: October 30, 2014
• Last Update Posted: October 14, 2022
• Sponsor: Clementia Pharmaceuticals Inc.
• Information provided by (Responsible Party): Ipsen ( Clementia Pharmaceuticals Inc. )

Study Description

Brief Summary:

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO), i.e., abnormal bone formation, often associated with painful, recurrent episodes of soft tissue swelling (flare-ups). Lesions begin in early childhood and lead to progressive ankyloses of major joints with resultant loss of movement.

In this study, the ability of different palovarotene dosing regimens to prevent the formation of new HO will be evaluated in adult and pediatric participants with FOP.

Condition or disease	Intervention/treatment	Phase
Fibrodysplasia Ossificans Progressiva	Drug: Palovarotene dose level 1; Drug: Palovarotene dose level 2; Drug: Palovarotene dose level 3; Drug: Palovarotene dose level 4	Phase 2

Detailed Description:

The main objective of this Phase 2, multicenter, open-label study is to evaluate the safety and efficacy of different palovarotene dosing regimens in participants with FOP. Efficacy will be assessed based on the ability of palovarotene to prevent the formation of new heterotopic ossification (HO) as assessed by low-dose whole body computed tomography (WBCT) scan, excluding head.

The study was divided into four parts: Part A (completed on July 2017), Part B (completed on October 2018), Part C (completed) and Part D (completd). Each part was associated with revised palovarotene treatment regimens.

In Part A, all pediatric and adult participants who successfully completed Study PVO-1A-201 were enrolled and followed for up to 36 months. Participants who had an eligible flare-up received 10 mg palovarotene daily for 14 days, followed by 5 mg palovarotene daily for 28 days (or weight-based equivalent).

In Part B, participants who successfully completed Study PVO-1A-201 (including any participant who participated in Part A of Study PVO-1A-202) as well as up to 20 new adult participants were followed for up to 24 months. The Adult Cohort included all participants with at least 90% skeletal maturity, regardless of age. The Pediatric Cohort included all participants with less than 90% skeletal maturity. Any Pediatric Cohort participant who achieved ≥90% skeletal maturity during Part B was considered for enrollment into the Adult Cohort at the discretion of the Investigator. Part B added a 5 mg palovarotene daily chronic treatment regimen administered between flare-ups for participants in the Adult Cohort for up to 24 months. Part B also increased the flare-up dosing to 20 mg palovarotene daily for 28 days, followed by 10 mg palovarotene daily for 56 days (or weight-adjusted equivalents in the Pediatric Cohort). Treatment could be extended if the flare-up was still ongoing.

In Part C, participants from Part B are being followed for up to an additional 48 months. There will be no new participants in Part C. All eligible participants, including skeletally immature participants, are receiving 5 mg palovarotene daily chronic treatment regimen (weight-adjusted doses for skeletally immature participants).

In Part D, annual post last dose of study treatment assessments for up to 2 years will be obtained in participants who were skeletally immature at the time of study treatment discontinuation in order to obtain longer-term safety data. No new participants will be enrolled into Part D.

Part C plus Part D duration will not exceed 48 months.

All participants will undergo all study procedures as specified in the respective schedule of assessments and for as long as they are not 100% skeletally mature.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 54 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
• Actual Study Start Date: October 27, 2014
• Actual Primary Completion Date: September 20, 2022
• Actual Study Completion Date: September 20, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Palovarotene dose level 1 (completed); Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).	Drug: Palovarotene dose level 1; Palovarotene was taken orally once daily at approximately the same time each day.
Experimental: Palovarotene dose level 2; Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).	Drug: Palovarotene dose level 2; Palovarotene will be taken orally once daily at approximately the same time each day.
Experimental: Palovarotene dose level 3; Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).	Drug: Palovarotene dose level 3; Palovarotene will be taken orally once daily at approximately the same time each day.
Experimental: Palovarotene dose level 4; All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.	Drug: Palovarotene dose level 4; Palovarotene will be taken orally once daily at approximately the same time each day.

Outcome Measures

Primary Outcome Measures :

1. Part A and Part B - Proportion of flare-up with no new HO ("responders") [ Time Frame: Week 12 ]
   Assessed by computed tomography (CT) scan (or plain radiographs for participants unable to undergo CT scan)
2. Part C - Annualized change in new HO volume [ Time Frame: Every 12 months for up to 72 months ]
   Assessed by low-dose whole body computed tomography (WBCT) (excluding head)

Secondary Outcome Measures :

1. Part A - Proportion of participants across the seven HO scores (0-6) [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component) ]
   Assessed by plain radiographs
2. Part A - Change from baseline in amount (area) of new heterotopic bone formed [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component) ]
   Assessed by plain radiographs
3. Part A - Change from baseline in cartilage, bone, angiogenesis, and inflammation biomarkers [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, and 12 (Flare-up Component) ]
4. Part A and Part B - Change from baseline in active range of motion (ROM) [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component) ]
   Assessed by goniometer
5. Part A and Part B - Change from baseline in ROM [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component) ]
   Assessed by Cumulative Analogue Joint Involvement Scale (CAJIS)
6. Part A and Part B - Participant and Investigator global assessment of movement [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component) ]
7. Part A - Change from baseline in pain and swelling (for participants under 8 years of age) [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, 9, and 12 (Flare-up Component) ]
   Assessed by numeric rating scale (NRS) or Faces Pain Scale-Revised (FPS-R)
8. Part A and Part B - Change from baseline in physical function [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, 8, 9, and 12 (Flare-up Component) ]
   Assessed by age-appropriate forms of the FOP-Physical Function Questionnaire (FOP-PFQ)
9. Part A and Part B - Change from baseline in physical and mental health [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, 8, 9, and 12 (Flare-up Component) ]
   Assessed by age-appropriate forms of the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale
10. Part A and Part B - Change from baseline in the use of assistive devices and adaptations for daily living by FOP participants [ Time Frame: Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component) ]
11. Part A and Part B - Presence of soft tissue swelling and/or cartilage [ Time Frame: Flare-up Weeks 6 and 12 (Flare-up Component) ]
    Assessed by magnetic resonance imaging (MRI) (or by US in participants unable to undergo MRI)
12. Part B - Change from baseline in amount of bone formation (volume) [ Time Frame: Flare-up Week 12 ]
    Assessed by low-dose CT scan (or area by plain radiographs for participants unable to undergo CT scan)
13. Part B - Change from baseline in cartilage, bone, angiogenesis, and inflammation biomarkers [ Time Frame: Flare-up Weeks 4, 8, and 12 ]
14. Duration of active, symptomatic flare-up (start date and end date) [ Time Frame: Up to 12 weeks ]
    Assessed by the participant and the Investigator
15. Part B (Chronic treatment) - Change from baseline in whole body burden of HO [ Time Frame: Study Months 12 and 24 ]
    Assessed by low-dose WBCT scan (excluding head)
16. Part B (Chronic treatment) - Number of flare-ups per participant-month overall, and by edema severity [ Time Frame: Up to 24 months ]
17. Part C - Percent of participants with new HO [ Time Frame: Every 12 months up to 72 months ]
18. Part C - Change from baseline in ROM [ Time Frame: Every 6 months up to 72 months ]
    Assessed by CAJIS
19. Part C - Change from baseline in physical function [ Time Frame: Every 6 months up to 72 months ]
    Assessed by age-appropriate forms of the FOP-PFQ
20. Part C - Change from baseline in physical and mental function for participants ≥15 years old and mental function for participants <15 years old [ Time Frame: Every 6 months up to 72 months ]
    Assessed by age-appropriate forms of the PROMIS Global Health Scale

Eligibility Criteria

• Ages Eligible for Study: 6 Years to 65 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Completion of Study PVO-1A-202/Part B.
• Written, signed, and dated informed consent and, for participants who are minors, age-appropriate participant assent (performed according to local regulations).
• Accessible for treatment with palovarotene and follow-up (able and willing to travel to a site for the initial and all follow-up clinic visits).
• Able to undergo low-dose, WBCT scan, excluding head.
• Females of child-bearing potential must have a negative blood or urine pregnancy test (with sensitivity of at least 50 mIU/mL) prior to administration of palovarotene.
• Male and FOCBP participants must agree to remain abstinent from heterosexual sex during treatment and for 1 month after treatment or, if sexually active, to use two effective methods of birth control during and for 1 month after treatment. Additionally, sexually active females of childbearing potential (FOCBP) participants must already be using two effective methods of birth control 1 month before treatment is to start. Specific risk of the use of retinoids during pregnancy, and the agreement to remain abstinent or use two effective methods of birth control will be clearly defined in the informed consent and the participant or legally authorized representatives.

Exclusion Criteria:

• Any reason that, in the opinion of the Investigator, would lead to the inability of the participant and/or family to comply with the protocol.
• Amylase or lipase >2x above the upper limit of normal or with a history of pancreatitis.
• Elevated aspartate aminotransferase or alanine aminotransferase >2.5x the upper limit of normal.
• Fasting triglycerides >400 mg/dL with or without therapy.
• Currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, herbal preparations containing vitamin A or beta carotene, or fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment.
• Participants experiencing suicidal ideation (type 4 or 5) or any suicidal behavior within the past month as defined by the Columbia Suicide Severity Rating Scale (C-SSRS).

Contacts and Locations

Locations

United States, California

University of California San Francisco, Division of Endocrinology and Metabolism

San Francisco, California, United States, 94143

United States, Minnesota

Mayo Clinic, Department of Medicine

Rochester, Minnesota, United States, 55905

United States, Pennsylvania

University of Pennsylvania, Center for FOP & Related Bone Disorders

Philadelphia, Pennsylvania, United States, 19104

Argentina

Hospital Italiano de Buenos Aires, Department of Pediatrics

Buenos Aires, Argentina

Australia, Queensland

Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI)

Woolloongabba, Queensland, Australia, 4102

France

Hôpital Necker-Enfants Malades, Department of Genetics

Paris, France

United Kingdom

The Royal National Orthopaedic Hospital, Brockley Hill

Stanmore, Middlesex, United Kingdom, HA7 4LP

Sponsors and Collaborators

Clementia Pharmaceuticals Inc.

Investigators

• Study Director: Ipsen Medical Director; Ipsen

More Information

Additional Information:

Website for the International FOP Association 

Website for the French FOP Association 

Click here for more information about this study: A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva (FOP) 

Publications:

Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, Chandraratna RA, Mishina Y, Enomoto-Iwamoto M, Pacifici M, Iwamoto M. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3. Erratum In: Nat Med. 2012 Oct;18(10):1592.

• Responsible Party: Clementia Pharmaceuticals Inc.
• ClinicalTrials.gov Identifier: NCT02279095
• Other Study ID Numbers: PVO-1A-202; 2014-002496-28 ( EudraCT Number )
• First Posted: October 30, 2014
• Last Update Posted: October 14, 2022
• Last Verified: October 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ipsen ( Clementia Pharmaceuticals Inc. ):

Open-label extension study; Clinical trial Phase 2; Efficacy and safety; Heterotopic ossification; Fibrodysplasia Ossificans Progressiva; Flare-up; Palovarotene; Retinoic acid receptor agonist; Retinoic acid receptor gamma agonist; Clementia; Myositis Ossificans Progressiva; Munchmeyer's Disease; FOP; Ipsen

Additional relevant MeSH terms:

Myositis Ossificans; Myositis; Muscular Diseases; Musculoskeletal Diseases